[Increasing ocular opacity in trisomy 13].
Palmowski-Wolfe
A M
AM
Augenklinik der Universität Basel, Schweiz. PalmowskiA@uhbs.ch
Messerli
J
J
Miny
P
P
Weber
P
P
D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use; D002386:Cataract / Q000150:complications / Q000151:congenital; D002882:Chromosomes, Human, Pair 13; D005901:Glaucoma / Q000150:complications / Q000151:congenital* / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D007223:Infant; D007429:Intraocular Pressure / Q000187:drug effects; D000077338:Latanoprost; D008297:Male; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology / Q000627:therapeutic use; D014130:Trabeculectomy; D014314:Trisomy
D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost